Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Joel E. Gallant(Johns Hopkins University), Andrew Cheng(Gilead Sciences (United States)), Anton Pozniak, Rafael Campo(University of Miami), Jeffrey Enejosa(Gilead Sciences (United States)), Steven L. Chuck(Gilead Sciences (United States)), Biao Lu(Gilead Sciences (United States)), Edwin DeJesus(Orlando Immunology Center), Brian Gazzard(British HIV Association), John J. Toole(Gilead Sciences (United States)), Damian J. McColl(Gilead Sciences (United States)), José Ramón Arribas(Hospital Universitario La Paz)
Cited by 886
Related Papers
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
|Science|1997|3.1k
Treatment for Adult HIV Infection
|JAMA|2006|1k
Antiretroviral Therapy in Adults
|JAMA|2000|1k
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Infections with<i>Cryptococcus neoformans</i>in the Acquired Immunodeficiency Syndrome
|New England Journal of Medicine|1989|801